Yes , they are a competition to the point..

70% of VIP ( Vasoactive Intestinal Polypeptide ) is located in humans in lungs , and covid is much more then lungs disease .

This is why I believe that generally Leronlimab might do better in most of the patients , but I also believe , base what I know now , that Leronlimab will do very well in combo with Aviptadil in some patients ...


IMO...